BioMarin reports phase 3 BMN 270 patient diagnosed with leukemia; initial tests find no link to therapy

BIOMARIN PHARMACEUTICAL INC

BMN 270 phase 3 participant diagnosed with B-ALL; 85% of leukemic cells had Ph-like translocation.
BMN 270 vector DNA in leukemic cells was negligible (<1 copy per 500 cells), suggesting no clonal expansion.
No trial hold; all BMN 270 studies continue enrollment; DSMB agreed no modification needed.
BioMarin remains on track to resubmit BMN 270 BLA to FDA by end of September 2022.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.